Dr. Amin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1021 Morehead Medical Dr
Suite 5300
Charlotte, NC 28204Phone+1 980-442-2000Fax+1 980-442-5111
Summary
- Dr. Asim Amin is a highly experienced oncologist based in Charlotte, NC. He completed his fellowship in Medical Oncology at Georgetown University Hospital and has particular experience in immunotherapy, cutaneous malignancies and renal cell carcinoma. Dr. Amin has been recognized for his work with an award from Castle Connolly as a Regional Top Doctor since 2014. He has contributed to the oncology field with numerous publications in esteemed journals and been cited extensively. He has played a crucial role in significant clinical trials and serves as chief of cutaneous malignancies section at the Levine Cancer Institute, Atrium Health.
Education & Training
Georgetown University HospitalFellowship, Medical Oncology, 1996 - 1999
MedStar Health/Georgetown University HospitalFellowship, Hematology and Medical Oncology, 1997 - 1998
Providence HospitalResidency, Internal Medicine, 1994 - 1996
Zucker School of Medicine at Hofstra/Northwell at Staten Island University HospitalInternship, Internal Medicine, 1993 - 1994
King Edward Medical UniversityClass of 1985
Certifications & Licensure
NC State Medical License 2005 - 2025
DC State Medical License 1997 - 2006
MD State Medical License 1996 - 2000
IL State Medical License 1990 - 1993- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Clinical Trials
- S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
- PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Publications & Presentations
PubMed
- 313 citationsSafety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 StudyHans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante, Brian I. Rini, David F. McDermott
Journal of Clinical Oncology. 2017-07-05 - 57 citationsImmune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional respondersAlice Boilève, Maria I. Carlo, Philippe Barthélémy, Stéphane Oudard, Delphine Borchiellini
Journal for Immunotherapy of Cancer. 2018-12-27 - 445 citationsA Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesoni...Jeffrey S. Weber, John A. Thompson, Omid Hamid, David R. Minor, Asim Amin
Clinical Cancer Research. 2009-09-01
Press Mentions
I’ll Never Stop FightingAugust 22nd, 2019
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
